News & Updates

Infliximab trumps other biologics as maintenance drug in CD
Infliximab trumps other biologics as maintenance drug in CD
19 Feb 2025 byStephen Padilla

Among the many biologics used to treat adults with moderate-to-severe Crohn’s disease (CD), infliximab subcutaneous (SC) 120 mg every 2 weeks (Q2W) demonstrates the highest efficacy in clinical remission during maintenance treatment of 52 to 64 weeks’ duration, according to the results of a recent study presented at CCC 2025.

Infliximab trumps other biologics as maintenance drug in CD
19 Feb 2025